| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4143062 | Anales de Pediatría | 2009 | 9 Pages |
Abstract
We conclude that subcutaneous administration of 16% SCIg is a safe and cost-effective alternative to IVIg for replacement therapy of primary antibody deficiencies. Median trough serum IgG levels were higher with SCIg. Local AE were common but mild and the incidence decreased over time. Quality of life is significantly improved.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
M. Maroto Hernando, P. Soler PalacÃn, A. MartÃn Nalda, M. Oliveras Arenas, T. Español Boren, C. Figueras Nadal,